Antiangiogenic Therapy for Children With Recurrent Medulloblastoma, Ependymoma, ATRT and Rare CNS Tumors
Public ClinicalTrials.gov record NCT01356290. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Phase II Study of Metronomic and Targeted Anti-angiogenesis Therapy for Children With Recurrent/Progressive Medulloblastoma, Ependymoma, ATRT and Rare CNS Tumors
Study identification
- NCT ID
- NCT01356290
- Recruitment status
- Recruiting
- Study type
- Interventional
- Phase
- Phase 2
- Lead sponsor
- Medical University of Vienna
- Other
- Enrollment
- 232 participants
Conditions and interventions
Interventions
- Bevacizumab Drug
- Thalidomide Drug
- Celecoxib Drug
- Fenofibric acid Drug
- Etoposide Drug
- Cyclophosphamide Drug
- Etoposide phosphate Drug
- Cytarabine Drug
- Temozolomide (TMZ) Drug
- Irinotecan Drug
Drug
Eligibility (public fields only)
- Age range
- Up to 19 Years
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Mar 31, 2014
- Primary completion
- Mar 31, 2030
- Completion
- Mar 31, 2030
- Last update posted
- Feb 22, 2026
2014 – 2030
United States locations
- U.S. sites
- 4
- U.S. states
- 4
- U.S. cities
- 4
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Ann & Robert H. Lurie Children's Hospital of Chicago | Chicago | Illinois | 60611-2605 | Terminated |
| Dana-Farber Cancer Institute and Boston Children's Hospital | Boston | Massachusetts | 02215 | Terminated |
| Helen DeVos Children's Hospital | Grand Rapids | Michigan | 48503 | Recruiting |
| Dell Children's Medical Group SFC-HEM/ONC | Austin | Texas | 78723 | Recruiting |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 18 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT01356290, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Feb 22, 2026 · Synced Jul 21, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT01356290 live on ClinicalTrials.gov.